new_0222_0417|TALS|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_0222_0417|TALS|Long Name|1|1|Talaris Therapeutics Inc Total Current Assets (Quarterly) (USD)|Talaris Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Talaris Therapeutics Inc Inventories (Quarterly) (USD)|Talaris Therapeutics Inc Net PP&E (Quarterly) (USD)|Talaris Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Talaris Therapeutics Inc Total Liabilities (Quarterly) (USD)|Talaris Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Talaris Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Talaris Therapeutics Inc Total Deposits (Quarterly) (USD)|Talaris Therapeutics Inc Book Value (Quarterly) (USD)|Talaris Therapeutics Inc Retained Earnings (Quarterly) (USD)|Talaris Therapeutics Inc Treasury Stock (Quarterly) (USD)|Talaris Therapeutics Inc EV to Revenues|Talaris Therapeutics Inc EV to Earnings|Talaris Therapeutics Inc EV to Free Cash Flow|Talaris Therapeutics Inc EV to Assets (Quarterly)|Talaris Therapeutics Inc PS Ratio|Talaris Therapeutics Inc PE Ratio|Talaris Therapeutics Inc Price to Book Value|Talaris Therapeutics Inc PEG Ratio|Talaris Therapeutics Inc Debt to Equity Ratio|Talaris Therapeutics Inc Dividend Yield|Talaris Therapeutics Inc Shareholder Yield (TTM)|Talaris Therapeutics Inc Percent of Shares Outstanding Short|Talaris Therapeutics Inc Total Receivables (Quarterly) (USD)|Talaris Therapeutics Inc Total Payables (Quarterly) (USD)|Talaris Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Talaris Therapeutics Inc Return on Invested Capital|Talaris Therapeutics Inc Quality Ratio Score|Talaris Therapeutics Inc Momentum Score|Talaris Therapeutics Inc Beta (1Y)|Talaris Therapeutics Inc Sustainable Growth Rate (TTM)|Talaris Therapeutics Inc Institutional Investor Ownership Percentage|Talaris Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Talaris Therapeutics Inc Total Employees (Annual)|Talaris Therapeutics Inc EPS Diluted (Quarterly) (USD)|Talaris Therapeutics Inc Shares Outstanding|Talaris Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Talaris Therapeutics Inc Ordinary Shares Number (Quarterly)|Talaris Therapeutics Inc Payout Ratio|Talaris Therapeutics Inc Quick Ratio (Quarterly)|Talaris Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Talaris Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Talaris Therapeutics Inc Effective Tax Rate (TTM)|Talaris Therapeutics Inc Return on Equity|Talaris Therapeutics Inc Net Income (TTM) (USD)|Talaris Therapeutics Inc Revenue (TTM) (USD)|Talaris Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Talaris Therapeutics Inc Revenue (Quarterly) (USD)|Talaris Therapeutics Inc Gross Profit (Quarterly) (USD)|Talaris Therapeutics Inc SG&A Expense (Quarterly) (USD)|Talaris Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Talaris Therapeutics Inc Net Income (Quarterly) (USD)|Talaris Therapeutics Inc Net Interest Income (Quarterly) (USD)|Talaris Therapeutics Inc Price (USD)|Talaris Therapeutics Inc Total Return Price (USD)|Talaris Therapeutics Inc Enterprise Value (USD)|Talaris Therapeutics Inc 30-Day Average Daily Volume|Talaris Therapeutics Inc 1 Year Price Returns (Daily)
new_0222_0417|TALS|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_0222_0417|TALS||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly
new_0222_0417|TALS||5|5|91|91|0|91|0|91|91|91|0|91|91|0|0|0|1.44444444444|0|0|0|1.43827160494|0|0|1.44444444444|0|15.4117647059|90|91|91|0|0|0|0|0|30.625|91.3333333333|183|91.3333333333|26|0|91|0|0|91.3333333333|91.4|0|0|91|0|0|0|0|91.3333333333|91.3333333333|91.3333333333|91.3333333333|1.44221105528|1.44221105528|1.44444444444|1.44378698225|0
new_0222_0417|TALS||6|6|3|3|0|3|0|3|3|3|0|3|3|0|0|0|198|0|0|0|162|0|0|198|0|17|1|3|3|0|0|0|0|0|8|6|1|6|7|0|3|0|0|6|5|0|0|3|0|0|0|0|6|6|6|6|199|199|198|169|0
new_0222_0417|TALS||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_0222_0417|TALS|202003|202003|202003||||||||||||||||||||||||||||||||||21.1926||-0.2288||||||-0.2288|||||||||1.439|-4.848|-4.848|0.126|||||
new_0222_0417|TALS|202006|202006|202006||||||||||||||||||||||||||||||||||21.1926||-0.22||||||-0.22|0||||||||1.335|-4.663|-4.663|0.074|||||
new_0222_0417|TALS|202009|202009|202009||||||||||||||||||||||||||||||||||21.1926||-0.3028||||||-0.3028|0||||||||2.182|-6.417|-6.417|-0.279|||||
new_0222_0417|TALS|202012|202012|202012|150.751|149.488||2.013||4.773|3.404|1.369||148.005|-43.014||||||||||||||0.374|0.923|0.003|||||||21.1926||-0.3199|||41.2369|||-0.3199||||-22.707|||||2.453|-6.779|-6.779|0.056|||||
new_0222_0417|TALS|202103|202103|202103|142.803|140.101||2.083||191.366|3.581|187.785||-46.466|-52.313||||||||||||||0.477|0.817|0.001|||||||41.2369|82|-0.2255|||41.2369|||-0.2255||||-27.158|||||2.537|-9.299|-9.299|-0.294|||||
new_0222_0417|TALS|202105|202103|202103|||||||||||||||-21.6477|||||||0||0.0708|||||||||19.1606||||41.2369||||||||||||||||||16.07|16.07|522.576||
new_0222_0417|TALS|202106|202106|202106|270.47|266.22||2.255||5.461|4.661|0.8||267.353|-63.665||||-10.4298||||2.2292|||0||1.4573||1.265|0.004||||||89.1372|27.3732||-0.41|40.5711||40.5711|||-0.41|-139.523|||-33.847|||||3.487|-11.352|-11.352|-0.295|14.69|14.69|329.7695|201977.3|
new_0222_0417|TALS|202107|202106|202106|||||||||||||||-9.3006||||2.0957|||0||1.6482|||||||||89.6174||||||||||||||||||||||13.81|13.81|294.0669|131764.1667|
new_0222_0417|TALS|202108|202106|202106|||||||||||||||-6.7622||||1.7955|||0||1.9637|||||||||87.9396||||41.3459||||||||||||||||||11.61|11.61|213.8059|42412.3333|
new_0222_0417|TALS|202109|202109|202109|258.227|254.734||2.994||5.676|4.982|0.694||255.649|-76.606||||-7.9703||||2.1595|||0||2.0149||1.182|0.004||||||68.0695|40.6694|107|-0.32|40.7127||40.7127|||-0.32|0|||-40.371|||||3.874|-12.941|-12.941|0.116|13.56|13.56|297.3302|41197|
new_0222_0417|TALS|202110|202109|202109|||||||||||||||-11.6044||||2.6898|||0||1.9801|||||||||68.1581||||||||||||||||||||||16.89|16.89|432.9035|39228.3333|
new_0222_0417|TALS|202111|202109|202109|||||||||||||||-7.5384||||2.0965|||0||2.4664|||||||||66.9805||||41.3546||||||||||||||||||12.96|12.96|281.2216|64778.2667|
new_0222_0417|TALS|202112|202112|202112|||||||||||||||-10.1214||||2.4734|||0||3.4562|||||||||70.5765||||||||||||||||||||||15.29|15.29|377.5778|162452.0667|
new_0222_0417|TALS|202201|202112|202112|||||||||||||||-3.6252||||1.5254|||0||2.7334|||||||||65.9841||||||||||||||||||||||9.43|9.43|135.2399|125318.0333|
new_0222_0417|TALS|202202|202112|202112|||||||||||||||-2.9934||||1.3588|||0|||||||||||||||||||||||||||||||||8.4|8.4|111.6678|53991.1|